Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 6/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17371329 | 0.81 | GAA (0.59) | GAAALDH1A1HPGDTSHRHTT | |
| SCHEMBL11752618 | 0.81 | ALDH1A1 (0.59) | GAAALDH1A1HPGDTSHRHTT | |
| SCHEMBL13622072 | 0.80 | GAA (0.58) | GAAALDH1A1HPGDTSHRHTT | |
| SCHEMBL12657060 | 0.80 | ALDH1A1 (0.58) | GAAALDH1A1HPGDTSHRHTT | |
| SCHEMBL166777 | 0.80 | TSHR (0.62) | GAAALDH1A1HPGDTSHRHTT | |
| SCHEMBL8569757 | 0.79 | KEAP1 (0.50) | GAAALDH1A1HPGDKMT2AHSD17B10 | |
| SCHEMBL11341066 | 0.77 | TSHR (0.75) | GAAALDH1A1HPGDTSHRHTT | |
| SCHEMBL1387769 | 0.77 | TSHR (0.75) | GAAALDH1A1HPGDTSHRHTT | |
| SCHEMBL30593956 | 0.77 | TSHR (0.75) | GAAALDH1A1HPGDTSHRHTT | |
| SCHEMBL12313326 | 0.77 | GAA (0.54) | GAAALDH1A1HPGDTSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258967-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258967-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | GAA 823/4885ALDH1A1 4394/4885HPGD 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.